Filing Details
- Accession Number:
- 0000908834-25-000097
- Form Type:
- 13D Filing
- Publication Date:
- 2025-03-09 20:00:00
- Filed By:
- SCHULER JACK W
- Company:
- Aspira Women's Health Inc. (NASDAQ:AWH)
- Filing Date:
- 2025-03-10
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
SCHULER JACK W | 6,536 | 2,712,156 | 6,536 | 2,712,156 | 2,718,692 | 14.7% |
Jack W. Schuler Living Trust | 0 | 2,712,156 | 0 | 2,712,156 | 2,712,156 | 14.7% |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 17)
|
Aspira Women's Health Inc. (Name of Issuer) |
Common Stock, par value $0.001 per share (the "Shares") (Title of Class of Securities) |
04537Y208 (CUSIP Number) |
Jack W. Schuler PO Box 531, Lake Bluff, IL, 60044 (520) 906-2991 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/06/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.


The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
CUSIP No. | 04537Y208 |
1 |
Name of reporting person
SCHULER JACK W | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
PF | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
2,718,692.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
14.7 % | ||||||||
14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
CUSIP No. | 04537Y208 |
1 |
Name of reporting person
Jack W. Schuler Living Trust | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
WC | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
ILLINOIS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
2,712,156.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
14.7 % | ||||||||
14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
Item 1. | Security and Issuer |
(a) | Title of Class of Securities:
Common Stock, par value $0.001 per share (the "Shares") |
(b) | Name of Issuer:
Aspira Women's Health Inc. |
(c) | Address of Issuer's Principal Executive Offices:
12117 Bee Caves Road, Building III, Suite 100, Austin,
TEXAS
, 78738. |
Item 4. | Purpose of Transaction |
This Amendment No. 17 to Schedule 13D (this "Amendment") hereby amends and supplements Item 4 by adding the following thereto:
"The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4.
On March 6, 2025, the Trust purchased from the Issuer the Convertible Note pursuant to the March 2025 Purchase Agreement (in each case as defined and further described in Item 6 below)." | |
Item 5. | Interest in Securities of the Issuer |
(a) | This Amendment hereby amends and restates Item 5(a) in its entirety as follows:
"The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 17,675,022 Shares outstanding as of January 27, 2025, as reported by the Issuer in its Form S-1/A filed with the Securities and Exchange Commission (the "SEC") on February 11, 2025." |
(b) | This Amendment hereby amends and restates Item 5(b) in its entirety as follows:
"The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference." |
(c) | This Amendment hereby amends and restates Item 5(c) in its entirety as follows:
"Neither Mr. Schuler nor the Trust has effected any transactions in the Shares during the 60 days prior to the date hereof." |
(d) | This Amendment hereby amends and restates Item 5(d) in its entirety as follows:
"The Trust has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by it and the Shares that it has the right to acquire upon the conversion of the Convertible Note and the exercise of 2022 Warrants and January 2024 Warrants. Mr. Schuler is the sole trustee of the Trust." |
(e) | This Amendment hereby amends and restates Item 5(d) in its entirety as follows:
"Not applicable." |
Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
This Amendment hereby amends and supplements Item 6 by adding the following thereto:
"The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6.
March 2025 Purchase Agreement and Convertible Note
On March 5, 2025, the Trust entered into a Securities Purchase Agreement, dated as of such date, among the Issuer, the Trust, and the other purchasers party thereto (the "March 2025 Purchase Agreement"), pursuant to which the Trust purchased from the Issuer the Convertible Note (as defined below). The March 2025 Purchase Agreement contained customary terms and conditions.
The foregoing description of the March 2025 Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 16, which exhibit is hereby incorporated herein by reference.
On March 6, 2025, pursuant to the March 2025 Purchase Agreement, the Trust purchased from the Issuer a Senior Secured Convertible Note due 2030 in the principal amount of $200,000 (the "Convertible Note"). Each $0.25 principal amount of the Convertible Note is convertible by its holder at any time prior to maturity into one "Phase 1 Unit," consisting of (i) one share of Common Stock and (ii) a warrant to purchase, on the terms set forth therein, 2.25 shares of Common Stock.
The foregoing description of the Convertible Note does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 17, which exhibit is hereby incorporated herein by reference." | |
Item 7. | Material to be Filed as Exhibits. |
This Amendment hereby amends and supplements Item 7 by adding the following thereto:
"There is filed herewith as Exhibit 16 the form of March 2025 Purchase Agreement.
There is filed herewith as Exhibit 17 the form of Convertible Note." |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|